HEPION PHARMACEUTICALS INC (HEPA) Stock Price, Quote, News and Overview
NASDAQ:HEPA - Nasdaq - US4268974015 - Common Stock - Currency: USD
HEPA Quote, Performance and Key Statistics
0.318
-0.07 (-18.79%)
The current stock price of HEPA is 0.318 USD. In the past month the price decreased by -24.64%. In the past year, price decreased by -99.51%.
HEPA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 54.29 | 708.16B | ||
| JNJ | JOHNSON & JOHNSON | 15.29 | 369.72B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 19.6 | 302.74B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.51 | 221.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.8 | 216.78B | ||
| MRK | MERCK & CO. INC. | 10.01 | 196.20B | ||
| PFE | PFIZER INC | 7.33 | 133.39B | ||
| SNY | SANOFI-ADR | 13.85 | 129.48B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.52 | 97.42B | ||
| GSK | GSK PLC-SPON ADR | 6.99 | 77.70B | ||
| ZTS | ZOETIS INC | 27.18 | 73.00B | ||
| HLN | HALEON PLC-ADR | 22.49 | 49.69B |
Related stock screener links
About HEPA
Company Profile
Hepion Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Edison, New Jersey. The company went IPO on 2014-02-07. Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on artificial intelligence (AI)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (NASH), fibrotic diseases, hepatocellular carcinoma (HCC), and other chronic diseases. Its primary asset, Rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental disease models. Its drug candidate is intended to target multiple molecular pathways across the full spectrum of liver disease progression, from the triggering events that initiate disease to the pathological events that directly impair liver function and integrity. Its AI-POWR platform provides integrative, multi-variate, systems-biology bioinformatic and big-data analysis of proprietary pre-clinical and clinical data with publicly available multi-omic databases.
Company Info
HEPION PHARMACEUTICALS INC
399 Thornall St
Edison NEW JERSEY 08837 US
CEO: Robert Foster
Employees: 22
Phone: 17329024000
HEPION PHARMACEUTICALS INC / HEPA FAQ
What is the stock price of HEPION PHARMACEUTICALS INC today?
The current stock price of HEPA is 0.318 USD. The price decreased by -18.79% in the last trading session.
What is the ticker symbol for HEPION PHARMACEUTICALS INC stock?
The exchange symbol of HEPION PHARMACEUTICALS INC is HEPA and it is listed on the Nasdaq exchange.
On which exchange is HEPA stock listed?
HEPA stock is listed on the Nasdaq exchange.
What is HEPION PHARMACEUTICALS INC worth?
HEPION PHARMACEUTICALS INC (HEPA) has a market capitalization of 3.48M USD. This makes HEPA a Nano Cap stock.
How many employees does HEPION PHARMACEUTICALS INC have?
HEPION PHARMACEUTICALS INC (HEPA) currently has 22 employees.
What are the support and resistance levels for HEPION PHARMACEUTICALS INC (HEPA) stock?
HEPION PHARMACEUTICALS INC (HEPA) has a support level at 0.29 and a resistance level at 0.33. Check the full technical report for a detailed analysis of HEPA support and resistance levels.
Should I buy HEPION PHARMACEUTICALS INC (HEPA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of HEPA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of HEPA, evaluating the profitability, health, valuation and growth aspects
- HEPION PHARMACEUTICALS INC (HEPA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- HEPION PHARMACEUTICALS INC (HEPA) Sales and EPS estimates to see what analysts future expectations are.
- HEPION PHARMACEUTICALS INC (HEPA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- HEPION PHARMACEUTICALS INC (HEPA) Insider and Institutional Ownership to learn about the owners and their transactions.
- HEPION PHARMACEUTICALS INC (HEPA) Stock Chart to make your own analysis
- HEPION PHARMACEUTICALS INC (HEPA) Latest news and press-releases to stay up to date.
Does HEPION PHARMACEUTICALS INC (HEPA) stock pay dividends?
HEPA does not pay a dividend.
When does HEPION PHARMACEUTICALS INC (HEPA) report earnings?
HEPION PHARMACEUTICALS INC (HEPA) will report earnings on 2025-08-11.
What is the Price/Earnings (PE) ratio of HEPION PHARMACEUTICALS INC (HEPA)?
HEPION PHARMACEUTICALS INC (HEPA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-616).
What is the Short Interest ratio of HEPION PHARMACEUTICALS INC (HEPA) stock?
The outstanding short interest for HEPION PHARMACEUTICALS INC (HEPA) is 4.11% of its float. Check the ownership tab for more information on the HEPA short interest.
HEPA Technical Analysis
HEPA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to HEPA. HEPA has a bad profitability rating. Also its financial health evaluation is rather negative.
HEPA Financial Highlights
Over the last trailing twelve months HEPA reported a non-GAAP Earnings per Share(EPS) of -616. The EPS decreased by -4.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -817.53% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
HEPA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to HEPA. The Buy consensus is the average rating of analysts ratings from 7 analysts.